Nov 12, 2026 8:00am EST Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects
Nov 11, 2026 4:05pm EST Vivani Medical Reports Third Quarter 2026 Financial Results and Provides Business Update
Aug 13, 2026 4:05pm EDT Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 06, 2026 8:00am EDT Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Jul 07, 2026 7:35am EDT Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Jul 02, 2026 8:00am EDT Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.